Rand tallies a whopping $44B in biosimilar drug savings

One of the big, unanswered questions that is obsessing payers and biopharma execs alike is just how much a new generation of biosimilars can save the healthcare industry through lower prices. So Rand set out to model the marketing of these follow-ons, which are gradually gaining steam in the late-stage pipeline. Rand's number: $44.2 billion over 10 years. Rand based its estimate on an examination of more than 100 biologics on the market, including all the blockbusters. While consumers are expected to net some of the savings, the real winners may be physicians and hospitals, which administer these drugs. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.